IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy.
Anti-Allergic Agents
/ therapeutic use
Aspergillosis, Allergic Bronchopulmonary
/ drug therapy
Asthma
/ drug therapy
Chronic Disease
Conjunctivitis, Allergic
/ drug therapy
Dermatitis, Atopic
/ drug therapy
Food Hypersensitivity
/ drug therapy
Humans
Hypersensitivity, Immediate
/ drug therapy
Immunoglobulin E
/ immunology
Multimorbidity
Nasal Polyps
/ drug therapy
Omalizumab
/ therapeutic use
Rhinitis, Allergic
/ drug therapy
Sinusitis
/ drug therapy
Allergic bronchopulmonary aspergillosis
Allergic rhinitis
Asthma
Chronic rhinosinusitis with nasal polyps
Food allergies
Multimorbidities
Omalizumab
Rhinoconjunctivitis
Treatment
Vernal keratoconjunctivitis
Journal
The journal of allergy and clinical immunology. In practice
ISSN: 2213-2201
Titre abrégé: J Allergy Clin Immunol Pract
Pays: United States
ID NLM: 101597220
Informations de publication
Date de publication:
Historique:
received:
29
11
2018
revised:
27
02
2019
accepted:
28
02
2019
pubmed:
1
4
2019
medline:
18
8
2020
entrez:
1
4
2019
Statut:
ppublish
Résumé
Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma.
Identifiants
pubmed: 30928481
pii: S2213-2198(19)30245-4
doi: 10.1016/j.jaip.2019.02.030
pii:
doi:
Substances chimiques
Anti-Allergic Agents
0
Omalizumab
2P471X1Z11
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1418-1429Informations de copyright
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.